Luc90-BBz-CAR-T

Luc90-BBz-CAR-T is a second-generation chimeric antigen receptor (CAR) T-cell therapy designed to target the distal Variable (V) domain of the CS1 (SLAMF7) protein, which is highly and uniformly expressed on multiple myeloma cells. Developed by researchers at Washington University School of Medicine, the construct utilizes the Luc90 single-chain variable fragment (scFv) for antigen recognition, paired with a 4-1BB (CD137) co-stimulatory domain and a CD3ζ signaling domain. Unlike other CS1-targeting CARs that bind the proximal C2 domain (such as those derived from the HuLuc63 clone), Luc90-BBz-CAR-T targets the distal epitope. Preclinical studies demonstrate potent anti-myeloma activity in high tumor burden mouse models. Although CS1 expression on T-cells leads to CD8+ T-cell fratricide during production, the resulting CD4-dominant product maintains significant therapeutic efficacy, and the construct has been optimized with the MND promoter for clinical-grade production.

Other names

Luc90-CS1-CAR-TLuc-90-CS1-CAR-TLuc 90-CS1-CAR-Tanti-CS1 CAR-T (Luc90 clone)SLAMF7-CAR T cells (Luc90)